Alyeska Investment Group, L.P. Neurocrine Biosciences Inc Transaction History
Alyeska Investment Group, L.P.
- $25.4 Billion
- Q2 2025
A detailed history of Alyeska Investment Group, L.P. transactions in Neurocrine Biosciences Inc stock. As of the latest transaction made, Alyeska Investment Group, L.P. holds 30,000 shares of NBIX stock, worth $4.35 Million. This represents 0.01% of its overall portfolio holdings.
Number of Shares
30,000
Previous 206,368
85.46%
Holding current value
$4.35 Million
Previous $22.8 Million
83.48%
% of portfolio
0.01%
Previous 0.1%
Shares
5 transactions
Others Institutions Holding NBIX
# of Institutions
718Shares Held
102MCall Options Held
228KPut Options Held
336K-
Black Rock Inc. New York, NY14.2MShares$2.06 Billion0.04% of portfolio
-
Vanguard Group Inc Valley Forge, PA9.71MShares$1.41 Billion0.02% of portfolio
-
Dodge & Cox San Francisco, CA5.56MShares$805 Million0.45% of portfolio
-
Jpmorgan Chase & CO New York, NY4.73MShares$685 Million0.04% of portfolio
-
State Street Corp Boston, MA4.35MShares$630 Million0.02% of portfolio
About NEUROCRINE BIOSCIENCES INC
- Ticker NBIX
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 95,639,296
- Market Cap $13.9B
- Description
- Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...